138 related articles for article (PubMed ID: 38885453)
21. Case Report: A Case Report of a Histological Transformation of
Zhang Y; Qin Y; Xu H; Yao Q; Gao Y; Feng Y; Ren J
Pathol Oncol Res; 2021; 27():637745. PubMed ID: 34257603
[TBL] [Abstract][Full Text] [Related]
22. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
Ma HC; Liu YH; Ding KL; Liu YF; Zhao WJ; Zhu YJ; Chang XS; Chen YD; Xiao ZZ; Yu YY; Zhou R; Zhang HB
BMC Cancer; 2021 Nov; 21(1):1278. PubMed ID: 34836510
[TBL] [Abstract][Full Text] [Related]
23. ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma.
Zhu Y; Liu N; Guo W; Pu X; Guo H; Gan W; Li D
Pathol Res Pract; 2020 Dec; 216(12):153286. PubMed ID: 33197836
[TBL] [Abstract][Full Text] [Related]
24. ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report.
Gonzalez-Mosquera LF; Rous FA; Rogers A; Smith N; Goyert G; Gadgeel S
Clin Lung Cancer; 2024 Mar; 25(2):e77-e80. PubMed ID: 38057186
[TBL] [Abstract][Full Text] [Related]
25. EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.
Hui B; Zhang J; Shi X; Xing F; Shao YW; Wang Y; Zhang X; Wang S
Jpn J Clin Oncol; 2020 Dec; 50(12):1470-1474. PubMed ID: 32845005
[TBL] [Abstract][Full Text] [Related]
26. ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217.
Kuroda N; Trpkov K; Gao Y; Tretiakova M; Liu YJ; Ulamec M; Takeuchi K; Agaimy A; Przybycin C; Magi-Galluzzi C; Fushimi S; Kojima F; Sibony M; Hang JF; Pan CC; Yilmaz A; Siadat F; Sugawara E; Just PA; Ptakova N; Hes O
Mod Pathol; 2020 Dec; 33(12):2564-2579. PubMed ID: 32467651
[TBL] [Abstract][Full Text] [Related]
27. Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report.
He X; Jiao XD; Liu K; Qin BD; Wu Y; Ling Y; Liu J; Xu AQ; Song K; Zang YS
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036227
[No Abstract] [Full Text] [Related]
28. [ALK-HOOK1-rearranged renal cell carcinoma: report of a case].
Xu AD; Fu Y; Zhao XS; Fan X
Zhonghua Bing Li Xue Za Zhi; 2022 May; 51(5):464-466. PubMed ID: 35511648
[TBL] [Abstract][Full Text] [Related]
29. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
30. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
31. Alectinib in the treatment of ocular metastases of ALK rearranged non small cell lung cancer: Description of 2 case reports.
Gozzi E; Angelini F; Rossi L; Leoni V; Trenta P; Cimino G; Tomao S
Medicine (Baltimore); 2020 Jul; 99(27):e21004. PubMed ID: 32629718
[TBL] [Abstract][Full Text] [Related]
32. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
Zhu V; Ou SH
Expert Opin Drug Saf; 2017 Apr; 16(4):509-514. PubMed ID: 28276856
[TBL] [Abstract][Full Text] [Related]
33. Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review.
Iannantuono GM; Riondino S; Sganga S; Roselli M; Torino F
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409355
[TBL] [Abstract][Full Text] [Related]
34. Proteasome Inhibition Overcomes ALK-TKI Resistance in
Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
[TBL] [Abstract][Full Text] [Related]
35. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
36. First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report.
Scarfone G; Fumagalli M; Imbimbo M; Ceruti T; Cribiù FM; Di Loreto E; D'Incalci M; Facchin F; Fontana C; Garassino MC; Peccatori FA; Persico N; Signorelli D; Zucchetti M
J Thorac Oncol; 2021 May; 16(5):873-877. PubMed ID: 33795207
[TBL] [Abstract][Full Text] [Related]
37. Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model.
Funazo T; Tsuji T; Ozasa H; Furugaki K; Yoshimura Y; Oguri T; Ajimizu H; Yasuda Y; Nomizo T; Sakamori Y; Yoshida H; Kim YH; Hirai T
Mol Cancer Ther; 2020 Jun; 19(6):1320-1327. PubMed ID: 32217741
[TBL] [Abstract][Full Text] [Related]
38. The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis.
Fan J; Fong T; Xia Z; Zhang J; Luo P
Cancer Med; 2018 Oct; 7(10):4993-5005. PubMed ID: 30230699
[TBL] [Abstract][Full Text] [Related]
39. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
Ou SH; Ahn JS; De Petris L; Govindan R; Yang JC; Hughes B; Lena H; Moro-Sibilot D; Bearz A; Ramirez SV; Mekhail T; Spira A; Bordogna W; Balas B; Morcos PN; Monnet A; Zeaiter A; Kim DW
J Clin Oncol; 2016 Mar; 34(7):661-8. PubMed ID: 26598747
[TBL] [Abstract][Full Text] [Related]
40. YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation.
Tsuji T; Ozasa H; Aoki W; Aburaya S; Yamamoto Funazo T; Furugaki K; Yoshimura Y; Yamazoe M; Ajimizu H; Yasuda Y; Nomizo T; Yoshida H; Sakamori Y; Wake H; Ueda M; Kim YH; Hirai T
Nat Commun; 2020 Jan; 11(1):74. PubMed ID: 31900393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
